Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis
- 22 December 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (1) , 89-96
Abstract
Upgrade to cardiac resynchronization therapy (CRT) should be offered to patients who have developed pacing-induced cardiomyopathy with conventional right ventricular pacing. The extent to which these patients would also benefit from defibrillator back-up at the time of CRT upgrade is, however, unknown. Retrospective observational cohort study of 199 patients with pacing-induced cardiomyopathy and no history of sustained ventricular arrhythmia, including 104 upgraded to CRT-Pacemaker (CRT-P) and 95 upgraded to CRT-Defibrillator (CRT-D). The incidence of ventricular arrhythmias and the risk of sudden arrhythmic death obtained through a cause-of-death analysis based on clinical data and necropsy results were assessed and compared between the two groups. During a mean follow-up of 66 ± 24 months, 40 (38.5%) CRT-P patients died: three from primary arrhythmic death, while the remaining died of different causes (especially progressive heart failure), giving an incidence of 6.2 sudden arrhythmic deaths per 1000 patient-years. No episode of sustained VT was observed in the study group. There were no sudden arrhythmic deaths in the CRT-D group during a shorter follow-up, but the small and non-significant difference in all-cause mortality between CRT-Pacemaker (CRT-P) and CRT-D groups was mostly accounted for by an increase in non-sudden death. Women upgraded to CRT were at particularly low risk of all-cause mortality compared with men (HR 0.232, P = 0.048). Our findings suggest that patients who develop pacing-induced cardiomyopathy and are upgraded to CRT may not derive any significant benefit from the addition of the defibrillator in the absence of a history of ventricular arrhythmias.Keywords
This publication has 22 references indexed in Scilit:
- 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA)EP Europace, 2013
- Predictors of Super-Response to Cardiac Resynchronization Therapy and Associated Improvement in Clinical OutcomeJACC, 2012
- Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillatorHeart Rhythm, 2011
- Upgrading to resynchronization therapy after chronic right ventricular pacing improves left ventricular remodellingEuropean Heart Journal, 2010
- Incidence and prognostic significance of sustained ventricular tachycardias in heart failure patients implanted with biventricular pacemakers without a back-up defibrillator: results from the prospective, multicentre, Mona Lisa cohort studyEuropean Heart Journal, 2009
- Cardiac resynchronisation therapy for the treatment of heart failure: NICE technology appraisal guidanceHeart, 2007
- Frequency and Causes of Implantable Cardioverter-Defibrillator Therapies: Is Device Therapy Proarrhythmic?The American Journal of Cardiology, 2006
- Percent right ventricular pacing predicts outcomes in the DAVID trialHeart Rhythm, 2005
- Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart FailureNew England Journal of Medicine, 2005
- Adverse Effect of Ventricular Pacing on Heart Failure and Atrial Fibrillation Among Patients With Normal Baseline QRS Duration in a Clinical Trial of Pacemaker Therapy for Sinus Node DysfunctionCirculation, 2003